Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 10 chews Clear all
Completed Phase 1 Interventional Results available

Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)

NCT01708278
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Quercetin, Placebo - sugar chew
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Obinutuzumab, Bendamustine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease

NCT03356990
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Resistant Starch
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
5 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

NCT01470209
View directory record Official record
Conditions
Solid Tumors, Lung Cancer
Interventions
BKM120, Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chewing Gum for Weight Loss

NCT00971347
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Extra sugar-free chewing gum sticks, nutrition brochure
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 22, 2010 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

NCT02352558
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
BBI608, Dexamethasone, Bortezomib, Imatinib, Ibrutinib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 12, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Availability of Lipids in Almonds in Healthy Individuals

NCT00768417
View directory record Official record
Conditions
Obesity, Overweight
Interventions
10 chews, 25 Chews, 40 Chews
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 12, 2026, 10:35 PM EDT
Not yet recruiting Not applicable Interventional

Quit-Smoking Study for Native Hawaiians

NCT07075575
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking Cessation
Interventions
Nicotine Polacrilex Gum (2 mg), Cognitive Behavioral Group Therapy (CBGT)
Drug · Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 12, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

NCT06261060
View directory record Official record
Conditions
Familial Platelet Disorder, Hematopoietic
Interventions
Sirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

NCT05030272
View directory record Official record
Conditions
Tobacco Use Disorder, Mental Illness, Recurring Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Persistent Depressive Disorder
Interventions
Quit on the Go App (formerly "Learn to Quit " App), Brief advice, Nicotine patch, Smartphone coaching, Nicotine gum, Nicotine Lozenges
Device · Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Gum Chewing on Appetite and Digestion

NCT01070212
View directory record Official record
Conditions
The Null Hypothesis is That Food Rheology Will Have no Effect on These Indices, The Alternate Hypothesis is That Increased Mechanical Stimulation Will Result in Stronger Satiation/Satiety and Reduced Energy Intake, It is Hypothesized That the Effects of Mastication Will be Less Evident in Obese Compared to Lean Individuals
Interventions
soft gum, firm gum, no gum
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 12, 2026, 10:35 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT06248229
View directory record Official record
Conditions
Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions
Dyanavel XR, Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

NCT01419639
View directory record Official record
Conditions
Neurofibromatosis Type II
Interventions
Everolimus (RAD001) , Afinitor®
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

United States Pre-Market Tobacco Application Pharmacokinetics

NCT03719391
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
Interventions
Virginia Tobacco flavored JUUL 5% ENDS, Cool Mint flavored JUUL 5% ENDS, Mango flavored JUUL 5% ENDS, Creme Brulee flavored JUUL 5% ENDS, VUSE Solo e-cigarette, Nicorette White Ice Mint 4mg nicotine polacrilex gum, Usual Brand combustible cigarette
Other
Lead sponsor
Juul Labs, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Real-Time Caffeine Optimization During Total Sleep Deprivation

NCT04399083
View directory record Official record
Conditions
Caffeine, Sleep Deprivation, Shift-Work Related Sleep Disturbance
Interventions
Caffeine
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 12, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma

NCT04003896
View directory record Official record
Conditions
Biliary Tract Carcinoma
Interventions
Abemaciclib
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

NCT01500551
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 18 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
43
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 12, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

NCT06984744
View directory record Official record
Conditions
Dental Plaque Accumulation
Interventions
MIIP-E2 containing gum, placebo gum without MIIP-E2
Device
Lead sponsor
Lactea Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 12, 2026, 10:35 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Integrating Financial Coaching and Smoking Cessation Coaching

NCT05154669
View directory record Official record
Conditions
Smoking
Interventions
Financial counseling, Nicotine Replacement Therapy Agent - Patches, Nicotine Replacement Therapy Agent - Lozenges, Nicotine Replacement Therapy Agent - Gum
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotics, Immunity, Stress, and QofL

NCT05063305
View directory record Official record
Conditions
Stress, Quality of Life
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Sep 12, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products

NCT01964807
View directory record Official record
Conditions
Adverse Effect of Other Agents Primarily Affecting the Cardiovascular System, Initial Encounter
Interventions
Cigarette, NIDA test type with 16.6 mg nicotine, Cigarette, NIDA test type with <0.45 mg nicotine, Electronic cigarette with 18 mg/ml nicotine, Electronic Cigarette with no nicotine, Moist snuff, Sham Smoking, Secondhand cigarette smoke (SHS), Conditioned, filtered air, Sham Moist Snuff
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 12, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Cutaneous T-cell Lymphoma

NCT01637090
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Everolimus
Drug
Lead sponsor
Adam Lerner
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 12, 2026, 10:35 PM EDT